Sonus discusses new agent at AHA show
Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation
Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation agent that studiesindicate may be capable of producing myocardial perfusion at lowdoses with no hemodynamic effects.
Researchers from the University of California at San Diegoworking with the new agent presented data from animal studiesfor the first time at a major medical conference. QW7437 is aphase-shift emulsion that is stabilized with a negative-chargedsurfactant.
Investigators at the AHA meeting also presented data on thecompany's lead EchoGen agent, including an animal study by DukeUniversity researchers in which EchoGen was used to make 3-D measurementsof the left ventricle muscle mass in a single cardiac cycle.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
